Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oracle Corporation (ORCL) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Oracle Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Oracle Corporation trades at $153.28 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 14.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Oracle Corporation pays a 1.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

	ALNY	ORCL
Market Cap	$29.60B	$419.05B
Sector	Health	Technology
52-Week High	$491.22	$328.33
52-Week Low	$205.48	$114.99
Enterprise Value	$27.56B	$548.30B
Dividend Yield	—	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Oracle Corporation

Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.

Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ALNY

View details →

ORCL

Oracle and Supermicro report strong AI-driven growth but face cash flow challenges.24/7 Wall Street · 9 hours agoNeutral Quantinuum reports 279% revenue growth and forms key alliances, boosting quantum computing market position.Alex Lavoie · 10 hours agoBullish Microsoft shares rise after strong Q4, with $604 price target and 20% upside forecast.24/7 Wall Street · 11 hours agoBullish View details →

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.